Originally published by our sister publication, Clinical Oncology News
By David Wild
Researchers have identified a new biomarker to predict treatment response for myelodysplastic syndromes (MDS), specifically two groupings of hematopoietic stem cells that can predict response to treatment with venetoclax-based therapy.
“This research advocates that the stem cell profile of MDS should be considered to determine appropriate therapeutic approaches targeting these cells, particularly for